ERBA Diagnostics, Inc. Appoints Mohan Gopalkrishnan V.P. Operations
MIAMI--(BUSINESS WIRE)--Feb 7, 2013--ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Vice President - Operations. Mr. Gopalkrishnan will be responsible for managing ERBA Diagnostics’ daily operations and will be based in its Miami headquarters.
Kevin Clark, President and Chief Executive Officer of ERBA Diagnostics, said, “Mohan Gopalkrishnan’s appointment as V.P. Operations is a welcome strengthening of our management team. With a lifelong career in the healthcare industry, we expect that Mohan’s experience will strengthen the management team and improve efficiencies to help the company reach its full potential.” Mr. Gopalkrishnan, age 57, has over 30 years of experience in the diagnostics and medical devices industry. He started his career with Boehringer Mannheim in India and spent the last 15 years with Becton Dickinson, starting as a Business Leader for Medical Devices in India and then as ERP Leader for Asia and Business Director for Asia based in Singapore and, during the most recent five years, in the U.S. as Senior Director with global responsibility for a $550 million franchise.
Mr. Clark continued, “Mohan Gopalkrishnan has demonstrated that he is an experienced business leader with a consistent track record of building sustainable businesses across countries, regions and global platforms with strong strategic capabilities balanced with intense execution focus to drive growth through customer centric product and services innovation. We are confident that Mohan will be a catalyst of change for driving and sustaining growth and developing talent within our organization.” About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. ( www.erbadiagnostics.com ), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its legacy subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe) and ImmunoVision, Inc. (U.S.) – and through its recently acquired subsidiaries – Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.) and Drew Scientific Limited Co. (Europe).